The PrEP for Pregnant and Breastfeeding Women Toolkit is designed for use by policy makers, program implementers, and healthcare workers to expand provision of PrEP to PBFW. The evidence-informed materials are designed to be adapted to reflect local context and priorities, national policy and guidelines, and implementation context surrounding provision of PrEP to PBFW.
This fourth progress report of the Global HIV Prevention Coalition reviews the progress in the 28 focus countries, describing key developments in 2019–2020, identifying challenges and opportunities (including those associated with the COVID-19 pandemic) and outlining priorities for the years ahead.
The 16 Days of Activism Against Gender-Based Violence against women is an international campaign from November 25-December 10. Read more about the campaign's goals and where to access additional resources and support.
The HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women, was stopped early by the trial Data and Safety Monitoring Board (DSMB) as results showed CAB LA to be highly effective in preventing HIV acquisition.
A mixed‐method nested study among adolescents and young adults (AYA) in rural Lesotho, measuring the effect of home‐based secondary distribution of oral HIV self‐tests (HIVST) on coverage, as well as exploring how AYA perceive this HIV self‐testing model.
A study assessing changes in couples' sexual behaviors after HIV-negative partners discontinued pre-exposure prophylaxis (PrEP) and transitioned to rely primarily on their partner's adherence to antiretroviral therapy (ART) for prevention.